ProQR Therapeutics NV (PRQR)
1.98
+0.03
(+1.54%)
USD |
NASDAQ |
Jun 03, 16:00
1.98
0.00 (0.00%)
After-Hours: 20:00
ProQR Therapeutics Cash from Financing (TTM): -2.640M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -2.640M |
December 31, 2023 | -2.463M |
September 30, 2023 | 11.12M |
June 30, 2023 | -32.60M |
March 31, 2023 | -32.25M |
December 31, 2022 | -32.58M |
September 30, 2022 | -12.65M |
June 30, 2022 | 56.90M |
March 31, 2022 | 157.69M |
December 31, 2021 | 161.90M |
September 30, 2021 | 129.40M |
June 30, 2021 | 119.44M |
March 31, 2021 | 19.54M |
December 31, 2020 | 16.56M |
September 30, 2020 | 72.93M |
June 30, 2020 | 57.04M |
March 31, 2020 | 56.27M |
December 31, 2019 | 56.20M |
September 30, 2019 | 2.684M |
Date | Value |
---|---|
June 30, 2019 | 101.88M |
March 31, 2019 | 102.26M |
December 31, 2018 | 102.09M |
September 30, 2018 | 118.86M |
June 30, 2018 | 27.04M |
March 31, 2018 | 28.25M |
December 31, 2017 | 30.17M |
September 30, 2017 | 10.91M |
June 30, 2017 | 3.850M |
March 31, 2017 | 2.484M |
December 31, 2016 | 0.3951M |
September 30, 2016 | 0.6195M |
June 30, 2016 | 0.6308M |
March 31, 2016 | 2.010M |
December 31, 2015 | 1.798M |
September 30, 2015 | 2.120M |
June 30, 2015 | 106.63M |
March 31, 2015 | 159.44M |
December 31, 2014 | 159.42M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-32.60M
Minimum
Jun 2023
161.90M
Maximum
Dec 2021
45.22M
Average
37.87M
Median
Cash from Financing (TTM) Benchmarks
uniQure NV | 362.59M |
Merus NV | 260.02M |
argenx SE | -- |
Pharming Group | -0.88M |
Pharvaris NV | 353.20M |